Wegener's Granulomatosis Clinical Trial
Official title:
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Wegener's granulomatosis is a primary systemic vasculitis characterized by granulomatous and necrotizing inflammation predominantly affecting the respiratory tract and the kidneys. Conventional therapy of Wegener's granulomatosis with cyclophosphamide and corticosteroids is limited by incomplete remissions and a high relapse rate. Patients accumulate irreversible damage due to the disease and the consequences of prolonged drug exposure. The efficacy and safety of an alternative immunosuppressive drug, gusperimus, was evaluated in patients with refractory disease. A prospective, international, nulti-centre, single limb, open label study. Entry required active Wegener's granulomatosis with a Birmingham Vasculitis Activity Score (BVAS) >=4 and previous therapy with cyclophosphamide or methotrexate. Immunosuppressive drugs were withdrawn at entry and prednisolone doses adjusted according to clinical status. Gusperimus, 0.5mg/kg/day, was self-administered by subcutaneous injection in six treatment cycles of 21 days with a seven day washout between cycles. Cycles were stopped early for white blood count < 4,000/mm3. The primary endpoint was complete remission (BVAS=0 for at least 2 months) or partial remission (BVAS<50% of entry score). After the sixth cycle azathioprine was commenced and follow-up continued for a further six months.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 | |
| Completed |
NCT00072592 -
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
|
Phase 1 | |
| Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
| Completed |
NCT01167491 -
Study of One Protein Implicated in Wegener Disease
|
N/A | |
| Completed |
NCT00307593 -
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
|
N/A | |
| Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
| Terminated |
NCT01408836 -
Plasma Exchange for Renal Vasculitis
|
Phase 2/Phase 3 | |
| Completed |
NCT00001473 -
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
|
N/A | |
| Completed |
NCT00001256 -
Steroids and Methotrexate to Treat Systemic Vasculitis
|
Phase 2 | |
| Completed |
NCT00040248 -
Daclizumab to Treat Wegener's Granulomatosis
|
Phase 2 | |
| Completed |
NCT00005007 -
Etanercept for Wegener's Granulomatosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00307671 -
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
|
Phase 4 | |
| Completed |
NCT01988506 -
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
|
Phase 2 | |
| Recruiting |
NCT01066208 -
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
|
N/A | |
| Completed |
NCT00104299 -
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
|
Phase 2/Phase 3 | |
| Completed |
NCT00753103 -
Anti-Cytokine Therapy for Vasculitis
|
Phase 2 | |
| Completed |
NCT02176070 -
Reproductive Health in Men and Women With Vasculitis
|
N/A | |
| Completed |
NCT00468208 -
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00004567 -
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
|
Phase 2 | |
| Completed |
NCT00001901 -
Etanercept to Treat Wegener's Granulomatosis
|
Phase 2 |